Advertisement
Advertisement
U.S. Markets close in 22 mins
Advertisement
Advertisement
Advertisement
Advertisement

Immuron Limited (IMC.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.12500.0000 (0.00%)
At close: 4:10PM AEDT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1250
Open0.1300
Bid0.1250 x 0
Ask0.1300 x 0
Day's Range0.1250 - 0.1300
52 Week Range0.1250 - 0.2900
Volume361,129
Avg. Volume227,867
Market Cap28.012M
Beta (5Y Monthly)1.85
PE Ratio (TTM)N/A
EPS (TTM)-0.0360
Earnings DateApr 21, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.26
  • Benzinga

    Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19

    Immuron Limited (NASDAQ: IMRN) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials. The studies were conducted independently by the Hadassah Medical Center, Israel. IMM124E is used to manufacture Immuron's flagship commercially available and over-the-counter gastrointestinal and digestive health immune supplements Travelan and Protectyn. The paper examines the ability of IMM-124E to promote antiviral interferon-γ (IFNγ) T cell responses in a m

  • Benzinga

    18 Stocks Moving in Friday's Pre-Market Session

    Gainers eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) rose 25.5% to $14.41 in pre-market trading after the company, in collaboration with investigators at Baylor College of Medicine, announced the presentation of new data for zotatifin in animal models of triple-negative breast cancer at the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Camber Energy, Inc.. (NYSE: CEI) rose 19.7% to $2.13 in pre-market trading after jumping around 96% on Thursday. Immuro

  • GlobeNewswire

    IMM-124E – Demonstrates Antiviral T-Cell Immunity

    Key Points International Patent Filed Publication from the Hebrew University - Hadassah Medical Center Entitled: Augmented antiviral T cell immunity by oral administration of IMM-124E in preclinical models and a phase I/IIa clinical trial: A method for the prevention and treatment of COVID-19 MELBOURNE, Australia, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic pro

Advertisement
Advertisement